Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia

Blood Purification

Volumn 26, Issue 2, 2008, Pages 151-156

  Li, Han ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Erythropoietin; Hemodialysis; Iron sucrose; Renal anemia

Indexed keywords

CREATININE; CYANOCOBALAMIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SUCCINATE; FOLIC ACID; HEMOGLOBIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANEMIA; CHINA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 40949099590     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113529     Document Type: Article

References (21)

1. Portoles J, Lopez-Gomez JM, Aljama P: Anemia management and treatment response in patients on hemodialysis: the MAR study. J Nephrol 2006;19:352-360.
2. Covne D: Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy. Kidney Int 2006;101:S1-S3.
3. Riedel MK, Morgenstern T: Iron replacement in hemodialysis patients with a normal serum ferritin level. Dtsch Med Wochenschr 2004;129:1849-1853.
4. Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000;13:381-384.
5. Charytan C, Levin N, Saloum MA: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am J Kidney Dis 2001;37:300-307.
6. Michael B, Coyne DW, Steven C: Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-1839.
7. Li Y, Mei W, Jisheng P: Intravenous iron dextran treatment in chronic hemodialysis. Chin J Nephrol 2003;19:85-89.
8. Teehan B, et al: Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Transplant Proc 1996;212:63.
9. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D: Anemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006;38:295-310.
10. Petersen H, Jensen KE, Haghfelt TH: The cardio-renal anemia syndrome: what is it? With a focus on congestive heart failure (in Danish). Ugeskr Laeger 2006;168:1864-1867.
11. Roman RM, Lobo PI, Taylor RP, Goodkin DA, LaBrecque J, Powers KL, Bolton WK: Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. J Am Soc Nephrol 2004;15:1339-1346.
12. Spiegel DM: Anemia management in chronic kidney disease: what have we learned after 17 years? Semin Dial 2006;19:269-272.
13. Riedel MK, Morgenstern T: Iron replacement in hemodialysis patients with a normal serum ferritin level. Dtsch Med Wochenschr 2004;129:1849-1853.
14. Jacobs C, Frei D, Perkins AC: Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005;20:iii3-iii24.
15. Manaley HJ, Grabe DW: Determination of iron sucrose (Venofer) or iron dextran (Dex-Ferrum) removal by hemodialysis: an in-vitro study. BMC Nephrol 2004;5:1-7.
16. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(suppl 3):S58.
17. Locatelli F, Aljama P, Bárány P, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
18. Singh AK, Coyne DW, Shapiro W, Rizkala AR, DRIVE Study Group: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007;71:1163-1171.
19. Jayakumar S: Iron-dextran anaphylactic-like reaction after a negative test dose and subsequent successful administration of three doses. Dial Transplant 2000;29:198-201.
20. Hood SA, O'Brien M, Higgins R: The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Nephrol Nurs J 2000;27:41-42.
21. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ: Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol 2000;20:455-462.